Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR) should have a slogan that says “We love volatility.” The biotech stock now trades for just under $60 after its earnings report, but the 52-week trading range is $29.61 to $101.00. After a poor earnings reaction, we cannot help but wonder if Aegerion can rise by 70% as some are suggesting.
The impetus for this review is not just the earnings report. Bank of America Merrill Lynch issued a note on Aegerion that both maintained a Buy rating and maintained its $102 price target.
This $102 target implies about 70% upside. It is not the norm for a bulge bracket firm like Merrill Lynch to be out touting 70% upside in their Buy ratings. But then we looked around and saw that the Thomson Reuters consensus price target was roughly $101. The street high target is up at $115.
Given that this stock now being just under $60, we would remind readers that widespread optimism like this rarely holds when you see a negative news reaction. Analysts just cannot tell their bosses that they are sticking by that much upside. That being said, perhaps the target prices may start to drift lower.
So, what is it that Merrill Lynch sees? The firm said:
Following Aegerion’s fourth quarter results, we have not changed our $102 price objective and maintain our Buy rating on Aegerion. The company is exploring additional uses for Juxtapid in a pediatric indication and in Japan, which could lead to upside to our estimates. The expansion in sales and customer service capacity could help add new patients and keep compliance rates high. … We view today’s pullback as a particularly attractive buying opportunity as our January doctor survey indicated a large market for Juxtapid.
Juxtapid is the company’s first approved drug, and it targets homozygous familial hypercholesterolemia. This just launched in January of 2013, and Merrill Lynch expects that this company will begin to move to profitability in the third quarter of this year.
Aegerion shares were down 3.5% at $59.50 in Thursday morning trading.
Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.